Radiobiological issues in prospective carbon ion therapy trials

Piero Fossati, Naruhiro Matsufuji, Tadashi Kamada, Christian P. Karger

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Carbon ion radiotherapy (CIRT) is developing toward a versatile tool in radiotherapy; however, the increased relative biological effectiveness (RBE) of carbon ions in tumors and normal tissues with respect to photon irradiation has to be considered by mathematical models in treatment planning. As a consequence, dose prescription and definition of dose constraints are performed in terms of RBE weighted rather than absorbed dose. The RBE is a complex quantity, which depends on physical variables, such as dose and beam quality as well as on normal tissue- or tumor-specific factors. At present, three RBE models are employed in CIRT: (a) the mixed-beam model, (b) the Microdosimetric Kinetic Model (MKM), and (c) the local effect model. While the LEM is used in Europe, the other two models are employed in Japan, and unfortunately, the concepts of how the nominal RBE-weighted dose is determined and prescribed differ significantly between the European and Japanese centers complicating the comparison, transfer, and reproduction of clinical results. This has severe impact on the way treatments should be prescribed, recorded, and reported. This contribution reviews the concept of the clinical application of the different RBE models and the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.

Original languageEnglish
Pages (from-to)e1096-e1110
JournalMedical Physics
Volume45
Issue number11
DOIs
Publication statusPublished - Nov 1 2018

Fingerprint

Heavy Ion Radiotherapy
Relative Biological Effectiveness
Biological Models
Japan
Photons
Prescriptions
Reproduction
Neoplasms
Theoretical Models
Radiotherapy
Carbon
Ions

Keywords

  • carbon ion therapy
  • clinical trials
  • dose prescription
  • radiobiology
  • RBE modeling
  • relative biological effectiveness (RBE)

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging

Cite this

Radiobiological issues in prospective carbon ion therapy trials. / Fossati, Piero; Matsufuji, Naruhiro; Kamada, Tadashi; Karger, Christian P.

In: Medical Physics, Vol. 45, No. 11, 01.11.2018, p. e1096-e1110.

Research output: Contribution to journalReview article

Fossati, P, Matsufuji, N, Kamada, T & Karger, CP 2018, 'Radiobiological issues in prospective carbon ion therapy trials', Medical Physics, vol. 45, no. 11, pp. e1096-e1110. https://doi.org/10.1002/mp.12506
Fossati, Piero ; Matsufuji, Naruhiro ; Kamada, Tadashi ; Karger, Christian P. / Radiobiological issues in prospective carbon ion therapy trials. In: Medical Physics. 2018 ; Vol. 45, No. 11. pp. e1096-e1110.
@article{a8ee295582524c5eb20801e376f1b4c2,
title = "Radiobiological issues in prospective carbon ion therapy trials",
abstract = "Carbon ion radiotherapy (CIRT) is developing toward a versatile tool in radiotherapy; however, the increased relative biological effectiveness (RBE) of carbon ions in tumors and normal tissues with respect to photon irradiation has to be considered by mathematical models in treatment planning. As a consequence, dose prescription and definition of dose constraints are performed in terms of RBE weighted rather than absorbed dose. The RBE is a complex quantity, which depends on physical variables, such as dose and beam quality as well as on normal tissue- or tumor-specific factors. At present, three RBE models are employed in CIRT: (a) the mixed-beam model, (b) the Microdosimetric Kinetic Model (MKM), and (c) the local effect model. While the LEM is used in Europe, the other two models are employed in Japan, and unfortunately, the concepts of how the nominal RBE-weighted dose is determined and prescribed differ significantly between the European and Japanese centers complicating the comparison, transfer, and reproduction of clinical results. This has severe impact on the way treatments should be prescribed, recorded, and reported. This contribution reviews the concept of the clinical application of the different RBE models and the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.",
keywords = "carbon ion therapy, clinical trials, dose prescription, radiobiology, RBE modeling, relative biological effectiveness (RBE)",
author = "Piero Fossati and Naruhiro Matsufuji and Tadashi Kamada and Karger, {Christian P.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1002/mp.12506",
language = "English",
volume = "45",
pages = "e1096--e1110",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "John Wiley and Sons Ltd",
number = "11",

}

TY - JOUR

T1 - Radiobiological issues in prospective carbon ion therapy trials

AU - Fossati, Piero

AU - Matsufuji, Naruhiro

AU - Kamada, Tadashi

AU - Karger, Christian P.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Carbon ion radiotherapy (CIRT) is developing toward a versatile tool in radiotherapy; however, the increased relative biological effectiveness (RBE) of carbon ions in tumors and normal tissues with respect to photon irradiation has to be considered by mathematical models in treatment planning. As a consequence, dose prescription and definition of dose constraints are performed in terms of RBE weighted rather than absorbed dose. The RBE is a complex quantity, which depends on physical variables, such as dose and beam quality as well as on normal tissue- or tumor-specific factors. At present, three RBE models are employed in CIRT: (a) the mixed-beam model, (b) the Microdosimetric Kinetic Model (MKM), and (c) the local effect model. While the LEM is used in Europe, the other two models are employed in Japan, and unfortunately, the concepts of how the nominal RBE-weighted dose is determined and prescribed differ significantly between the European and Japanese centers complicating the comparison, transfer, and reproduction of clinical results. This has severe impact on the way treatments should be prescribed, recorded, and reported. This contribution reviews the concept of the clinical application of the different RBE models and the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.

AB - Carbon ion radiotherapy (CIRT) is developing toward a versatile tool in radiotherapy; however, the increased relative biological effectiveness (RBE) of carbon ions in tumors and normal tissues with respect to photon irradiation has to be considered by mathematical models in treatment planning. As a consequence, dose prescription and definition of dose constraints are performed in terms of RBE weighted rather than absorbed dose. The RBE is a complex quantity, which depends on physical variables, such as dose and beam quality as well as on normal tissue- or tumor-specific factors. At present, three RBE models are employed in CIRT: (a) the mixed-beam model, (b) the Microdosimetric Kinetic Model (MKM), and (c) the local effect model. While the LEM is used in Europe, the other two models are employed in Japan, and unfortunately, the concepts of how the nominal RBE-weighted dose is determined and prescribed differ significantly between the European and Japanese centers complicating the comparison, transfer, and reproduction of clinical results. This has severe impact on the way treatments should be prescribed, recorded, and reported. This contribution reviews the concept of the clinical application of the different RBE models and the ongoing clinical CIRT trials in Japan and Europe. Limitations of the RBE models and the resulting radiobiological issues in clinical CIRT trials are discussed in the context of current clinical evidence and future challenges.

KW - carbon ion therapy

KW - clinical trials

KW - dose prescription

KW - radiobiology

KW - RBE modeling

KW - relative biological effectiveness (RBE)

UR - http://www.scopus.com/inward/record.url?scp=85040313384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040313384&partnerID=8YFLogxK

U2 - 10.1002/mp.12506

DO - 10.1002/mp.12506

M3 - Review article

C2 - 30421806

AN - SCOPUS:85040313384

VL - 45

SP - e1096-e1110

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 11

ER -